Francesca Khani, MD

Associate Professor of Pathology and Laboratory Medicine

Contact & profiles

Appointments

Associate Professor of Pathology and Laboratory MedicinePrimary
Pathology and Laboratory Medicine · 2020–
Associate Professor of Pathology in Urology
Urology · 2020–
Physician
NewYork-Presbyterian Hospital

Past Appointments

Assistant Professor of Pathology in Urology
Urology · 2016–2020
Assistant Professor of Pathology and Laboratory Medicine
Pathology and Laboratory Medicine · 2015–2020
Clinical Associate in Pathology and Laboratory Medicine
Pathology and Laboratory Medicine · 2011–2014

Centers

Education

M.D.
Robert Wood Johnson Medical School, University of Medicine and Dentistry of New Jersey, 2010
B.S.
The College of New Jersey, 2006

Highlights

1
NPJ precision oncology · 2023
FKFrancesca Khani DJDavid J Pisapia BDBrian D. Robinson JMJuan Miguel Mosquera+2 more →HBHimisha Beltran
PMID: 37704749PMCID: PMC10499931DOIFirst author12 citations
2
American journal of clinical pathology · 2022
FKFrancesca Khani
PMID: 35932465DOISenior author17 citations
3
Cancer treatment and research communications · 2020
JMJuan Miguel Mosquera BDBrian D. Robinson DSDouglas S Scherr TMTimothy McClure FKFrancesca Khani
PMID: 32979705DOISenior author5 citations

4 grants

Co-I
Growth suppressive and oncogenic transcriptional programs controlled by the androgen receptor in prostate cancer
National Cancer Institute · 2025–2030
R01CA297829-01
Co-I
ESCAPE - Evaluation of Prostate Specific Membrane Antigen Positron Emission Tomography-Computed Tomography in Active Surveillance for Prostate Cancer
National Cancer Institute · 2024–2029
R37CA282407-01A1
Co-I
Optimization of Prostate-Specific Membrane Antigen-Targeted Radiation
Prostate Cancer Foundation · 2017–2027
17CHAL11
Co-I
Heating cold prostate tumors with PSMA-targeted alpha therapy and pembrolizumab
U.S. Department of Defense · 2020–2026
W81XWH-20-1-0706

Completed grants (3)

Sub-PI
Molecular and clinical correlates with prostate-specific membrane antigen (PSMA)-targeted radionuclide therapy
U.S. Department of Defense · 2019–2023 · via Dana-Farber Cancer Institute
W81XWH-18-1-0529
Co-I
Weill Cornell Medicine (WCM) SPORE in Prostate Cancer
National Cancer Institute · 2017–2023
P50CA211024-01A1
Co-I
Precision Interception of Aggressive Prostate Cancer in African American Men
National Cancer Institute · 2019–2021 · via Dana-Farber Cancer Institute
P20CA233255-01

1 study

PI
Prostate Cancers with MAPK Oncogenic Driver Mutations: Characterization of a Potentially Novel and Targetable Molecular Subclass Associated with Aggressive Behavior
Weill Medical College of Cornell University · OPEN TO ACCRUAL (as of 2019)